Obesity, diabetes and cancer: insight into the relationship from a cohort with growth hormone receptor deficiency

Diabetologia

Volumn 58, Issue 1, 2015, Pages 37-42

  Guevara Aguirre, Jaime ^a,b   Rosenbloom, Arlan L ^c  

^a UNIVERSIDAD SAN FRANCISCO DE QUITO   (Ecuador)

^b Instituto de Endocrinología IEMYR   (Ecuador)

^c UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Apoptosis; Cancer; Diabetes; Growth hormone receptor; IGF 1; Insulin; Obesity; Review

Indexed keywords

DNA; GLUCOSE; GROWTH HORMONE; GROWTH HORMONE RECEPTOR; INSULIN; OXIDIZING AGENT; SOMATOMEDIN; SOMATOMEDIN C;

APOPTOSIS; BODY FAT; BODY MASS; CANCER RISK; DIABETES MELLITUS; DNA DAMAGE; DNA STRAND BREAKAGE; ECUADOR; GENE MUTATION; GROWTH HORMONE DEFICIENCY; GROWTH HORMONE RECEPTOR DEFICIENCY; HUMAN; INSULIN SENSITIVITY; METABOLISM; MOLECULAR INTERACTION; NONHUMAN; NUTRITION; OBESITY; OVERNUTRITION; REVIEW; SIGNAL TRANSDUCTION; ADULT; BODY COMPOSITION; CASE CONTROL STUDY; COHORT ANALYSIS; COMPLICATION; DIABETES MELLITUS, TYPE 2; GENETICS; LARON SYNDROME; NEOPLASMS; PHYSIOLOGY;

ADULT; BODY COMPOSITION; CASE-CONTROL STUDIES; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; ECUADOR; HUMANS; INSULIN; INSULIN-LIKE GROWTH FACTOR I; LARON SYNDROME; NEOPLASMS; OBESITY;

EID: 84916212572     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-014-3397-3     Document Type: Review

References (62)

1. Burke-Gaffney H (1968) The history of medicine in African countries. Med Hist 12:31–412
2. Gohdes D, Kaufman S, Valway S (1993) Diabetes in American Indians. An overview. Diabetes Care 6:239–243
3. Steyn K, Fourie J, Bradshaw D (1992) The impact of chronic diseases of lifestyle and their major risk factors on mortality in South Africa. S Afr Med J 82:227–231
4. Reaven G (1988) Banting Lecture 1988. Role of insulin resistance in human disease. Diabetes 37:1595–1607
5. Phillips C, Keese-Guoyot E, McManus R et al (2012) High dietary saturated fat intake accentuates obesity risk associated with the fat mass and obesity-associated gene in adults. J Nutr 142:824–831
6. Belpomme D, Irigaray P, Hardell R et al (2007) The multitude and diversity of environmental carcinogens. Environ Res 105:414–429
7. Wolin KY, Carson K, Colditz GA (2010) Obesity and cancer. Oncologist 15:556–565
8. Knudeson A (2001) Two genetic hits to cancer. Nat Rev Cancer 2:157–162
9. Pollak M, Schernhammer E, Hankinson SE (2004) Insulin-like growth factors and neoplasia. Nat Rev Cancer 4:505–518
10. Hsu I, Kim S, Kabir M, Bergman R (2007) Metabolic syndrome, hyperinsulinaemia, and cancer. Am J Clin Nutr 86:867–871
11. Otake S, Takeda H, Suzuki Y et al (2005) Association of visceral fat accumulation and plasma adiponectin with colorectal adenoma: evidence for participation of insulin resistance. Clin Cancer Res 11:3642–3646
12. Thissen J, Ketelslegers H, Underwood L (1994) Nutritional regulation of the insulin like growth factors. Endocrinol Rev 15:80–101
13. Dupont J, Kahan J, Bao-He Q, Metzler P, Helman L, LeRoith D (2001) Insulin and IGF-I induce different patterns of expression in mouse fibroblast NIH-3T3 cells: identification by cDNA microarray analysis. Endocrinology 142:4969–4975
14. Guevara-Aguirre J, Al R, Guevara-Aguirre M, Saavedra J, Procel P (2013) Recommended IGF-I dosage causes greater fat accumulation and osseous maturation than lower dosage and may compromise long-term growth effects. J Clin Endocrinol Metab 98:839–845
15. Longo V, Fontana L (2010) Calorie restriction and cancer prevention: metabolic and molecular mechanisms. Trends Pharmacol Sci 31:89–98
16. Milazzo G, Giorgino F, Damante G et al (1992) Insulin receptor expression and function in human breast cancer cell lines. Cancer Res 52:3924–3930
17. Birsoy K, Possemato R, Lorbeer FK et al (2014) Metabolic determinants of cancer cell sensitivity to glucose limitation and biguanides. Nature 508:108–112
18. Baserga R, Peruzzi F, Krystof R (2003) The IGF-I receptor in cancer biology. Int J Cancer 107:873–877
19. Ferguson R, Novossyadlyy R, Fierz Y et al (2012) Hyperinsulinaemia enhances c-Myc-mediated mammary tumour development and advances metastatic progression to the lung in a mouse model of type 2 diabetes. Breast Cancer Res 14:R8
20. Klement R, Kämmerer U (2011) Is there a role for carbohydrate restriction in the treatment and prevention of cancer? Nutr Metab (Lond) 8:75
21. Drake I, Sonestedt D, Gulberg B et al (2012) Dietary intakes of carbohydrates in relation to prostate cancer risk: a prospective study in the Malmö diet and cancer cohort. Am J Nutr 96:1409–1418
22. Samani A, Yakar S, LeRoith D, Brodt P (2007) The role of the IGF-I system in cancer growth and metastasis: overview and recent insights. Endocr Rev 28:20–47
23. Rosenbloom A, Goldstein S, Yip CC (1976) Insulin binding to cultured human fibroblasts increases with normal and precocious aging. Science 193:412–415
24. Wijsman C, Rozing M, Streefland T, Leiden Longevity Study group et al (2011) Familial longevity is marked by enhanced insulin sensitivity. Aging Cell 10:114–121
25. Benetou B, Trichopoulou A, Orfanos P et al (2008) Conformity to traditional Mediterranean diet and cancer incidence: the Greek EPIC cohort. Brit J Cancer 99:191–195
26. Colman R, Anderson R, Johnson S et al (2009) Caloric restriction delays disease onset and mortality in rhesus monkeys. Science 325:201–204
27. Fruman DA, Rommel C (2014) PI3K and cancer: lessons, challenges and opportunities. Nat Rev Drug Discov 13:140–156
28. Ikeno Y, Hubbard GB, Lee S et al (2009) Reduced incidence and delayed occurrence of fatal neoplastic diseases in growth hormone receptor/binding protein knockout mice. J Gerontol A Biol Sci Med Sci 64:522–529
29. Dossus L, Kaaks R (2004) Nutrition, metabolic factors and cancer risk. Nat Cancer Rev 4:579–591
30. Sancar A, Lindsey-Boltz L, Unsal-Kacmaz K, Linn S (2004) Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Ann Rev Biochem 73:39–85
31. ε-(carboxymethyl)lysine and argpyrimidine. Ann NY Acad Sci 1043:725–733
32. Dingli D, Chalub F, Santos F, van Segbroeck S, Pacheco J (2009) Cancer phenotype as the outcome of an evolutionary game between normal and malignant cells. Br J Cancer 101:1130–1138
33. Halberg H, Henriksen M, Soderhamn N et al (2005) Effect of intermittent fasting and re-feeding on insulin action in healthy men. J Appl Physiol 99:2128–2136
34. Lee P, Durham S, Martínez V, Vásconez O, Powell D, Guevara-Aguirre J (1997) Kinetics of insulin-like growth factor (IGF) and IGF-binding protein responses to a single dose of growth hormone. J Clin Endocrinol Metab 82:2266–2274
35. Wolpin B, Michaud D, Giovannucci E et al (2007) Circulating insulin-like growth factor binding protein-I and the risk of pancreatic cancer. Cancer Res 67:7923–7928
36. Wu Y, Yakar S, Hennighausen L, LeRoith D (2002) Circulating insulin-like growth factor-I levels regulate colon cancer growth and metastasis. Cancer Res 62:1030–1035
37. Kolb E, Gorlick R, Maris J et al (2012) Combination testing (Stage 2) of the anti-IGF-I receptor antibody IMC-A12 with rapamycin by the pediatric preclinical testing program. Pediatr Blood Cancer 58:729–735
38. MacEwen E, Pastor J, Kutzke J et al (2004) IGF-I receptor contributes to the malignant phenotype in human and canine osteosarcoma. J Cell Biochem 92:77–91
39. Chhabra Y, Waters J, Brokks A (2011) Role of the growth hormone/IGF-I axis in cancer. Expert Rev Endocrinol Metab 6:71–84
40. Belfioiri A, Frasca F, Pandini G, Sciacca L, Vigneri R (2009) Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease. Endocr Rev 30:586–623
41. Rinderknecht E, Humbel R (1978) The amino acid sequence of human insulin growth factor-I and its structural homology with pro-insulin. J Biol Chem 253:2769–2776
42. Brzozowski A, Dodson E, Dodson G et al (2002) Structural origins of the functional divergence of human insulin growth factor-I and insulin. Biochemistry 41:9389–9397
43. Kim J, Accili D (2002) Signaling through IGF-I and insulin receptors: where is the specificity? Growth Horm IGF Res 12:84–90
44. Huo J, Xu S, Lin B, Chng WJ, Lam KP (2013) Fas apoptosis inhibitory molecule is upregulated by IGF-I signaling and modulates Akt activation and IRF4 expression in multiple myeloma. Leukemia 27:1165–1171
45. Hanahan D, Weinberg R (2000) The hallmarks of cancer. Cell 100:57–70
46. Renehan A, Zwahalen M, Minder C, O’Dwyer S, Shalet M, Egger M (2004) Insulin-like growth factor (IGF)-I, IGF-binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 363:1346–1353
47. Huang J, Morehouse C, Streicher K et al (2011) Altered expression of insulin receptor isoforms in breast cancer. PLoS ONE 6:e26177
48. Margel D, Urbach D, Lipscombe L et al (2013) Metformin use and all-cause and prostate cancer-specific mortality among men with diabetes. J Clin Oncol 31:3069–3075
49. Currie C, Poole C, Jenkins-Jones S, Gale E, Johnson J, Morgan C (2012) Mortality after incident cancer in people with and without type 2 diabetes: impact of metformin in survival. Diabetes Care 35:299–304
50. Madiraju AK, Erion DM, Rahimi Y et al (2014) Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase. Nature 510:542–546
51. Yakar S, LeRoith D, Brodt P (2005) The role of growth hormone /insulin-like growth factor axis in tumour growth and progression: lessons from animal models. Cytokine Growth Factor Rev 16:407–420
52. Resnicoff M, Copolla D, Sell C et al (1994) Growth inhibition of human melanoma cells in nude mice by anti-sense strategies to the type-I insulin-like growth factor receptor. Cancer Res 54:4848–4850
53. Suh Y, Atzmon G, Cho M et al (2008) Functionally significant insulin-like growth factor-I receptor mutations in centenarians. Proc Natl Acad Sci 105:3438–3442
54. Guevara-Aguirre J, Rosenbloom A, Fielder PJ, Diamond FB Jr, Rosenfeld RG (1993) Growth hormone receptor deficiency in Ecuador: clinical and biochemical phenotype in two populations. J Clin Endocrinol Metab 76:417–423
55. Rosenbloom AL, Guevara-Aguirre J, Rosenfeld RG, Fielder PJ (1990) The little women of Loja: growth hormone receptor deficiency in an inbred population of Southern Ecuador. N Engl J Med 323:1367–1374
56. Guevara-Aguirre J, Balasubramanian P, Guevara-Aguirre M et al (2011) Growth hormone receptor deficiency is associated with a major reduction in pro-aging signaling, cancer, and diabetes in humans. Sci Transl Med 3:70ra13
57. Steuerman R, Shivah O, Laron Z (2011) Congenital IGF-I deficiency tends to confer protection against postnatal development of malignancies. Eur J Endocrinol 164:485–489
58. Gebre-Medhin M, Kindblom LG, Wennbo H, Törnell J, Meis-Kindblom JM (2001) Growth hormone receptor is expressed in human breast cancer. Am J Pathol 158:1217–1222
59. Zhou D, Yang J, Huang WD, Wang J, Zhang Q (2013) siRNA-targeted inhibition of growth hormone receptor in human colon cancer SW480 cells. World J Gastroenterol 19:8108–8113
60. Guevara Aguirre J, Rosenbloom AL, Balasubramaniam P et al (2014) Enhanced insulin sensitivity in subjects with absent growth hormone receptor signaling despite increased body fat content. The Endocrine Society, Chicago, June 21-24, latebreaking abstract LB-OR02-1 (abstract)
61. Laron Z (2011) Insulin secretion and carbohydrate metabolism in patients with Laron syndrome: from hypoglycaemia to diabetes mellitus. In: Laron Z, Kopchick JJ (eds) Laron syndrome from man to mouse. Springer-Verlag, Berlin/Heidelberg, pp 259–272
62. Vicente TAR, Rocha IES, Salvatori R et al (2013) Lifetime congenital isolated GH deficiency does not protect from the development of diabetes. Endocr Connect 2:112–117